Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 9/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.33 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | YTHDF3 | Q7Z739 | 2/20 | 0.32 |
| ▸ | YTHDF1 | Q9BYJ9 | 2/20 | 0.32 |
| ▸ | YTHDF2 | Q9Y5A9 | 2/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30560025 | 0.89 | YTHDC1 (0.41) | YTHDC1LMNASMN1; SMN2SLC29A1P2RY1 | |
| SCHEMBL20164377 | 0.89 | YTHDC1 (0.41) | YTHDC1LMNASMN1; SMN2SLC29A1P2RY1 | |
| SCHEMBL20164346 | 0.87 | SLC29A1 (0.36) | LMNASMN1; SMN2SLC29A1GAAATG4B | |
| SCHEMBL30560041 | 0.85 | YTHDC1 (0.40) | YTHDC1LMNASMN1; SMN2P2RY1GAA | |
| SCHEMBL20164544 | 0.85 | YTHDC1 (0.40) | YTHDC1LMNASMN1; SMN2P2RY1GAA | |
| SCHEMBL20164329 | 0.85 | YTHDC1 (0.40) | YTHDC1LMNASMN1; SMN2P2RY1GAA | |
| SCHEMBL20164331 | 0.85 | YTHDC1 (0.40) | YTHDC1LMNASMN1; SMN2P2RY1GAA | |
| Hydrochloric Acid SCHEMBL20164312 | 0.85 | SLC29A1 (0.35) | LMNASMN1; SMN2SLC29A1GAAATG4B | |
| SCHEMBL20164506 | 0.84 | SLC29A1 (0.43) | LMNASLC29A1ATG4B | |
| SCHEMBL20179367 | 0.84 | SLC29A1 (0.43) | LMNASLC29A1ATG4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3316890-B1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME | NEURAD LTD (IL) | 2023-09-06 | — | — | EP | disclosed |
| US-10294228-B2 | Breathing control modulating compounds, and methods of making and using same | NEURAD LTD. (IL) | 2019-05-21 | — | — | US | disclosed |
| US-20180141953-A1 | Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same | NEURAD LTD. (IL) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141953-A1 | Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same | MTNR1B, CHRM3, PER2 | YTHDC1 2024/4885LMNA 1394/4885SMN1; SMN2 463/4885 |
| US-10294228-B2 | Breathing control modulating compounds, and methods of making and using same | MTNR1B, PDE3A, CHRM3 | YTHDC1 2085/4885LMNA 1200/4885SMN1; SMN2 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.